The Effect of Standard Dose Multivitamin Supplementation on Disease Progression in HIV-Infected Adults Initiating HAART: A Randomized Double Blind Placebo-Controlled Trial in Uganda

Below:  Trends in mean values of: CD4 cell count, weight, QoL scores, ALT and HB by trial arm. Solid line Multivitamin arm, broken line Placebo

Below:  Kaplan-Meier plots for confirmed HIV disease progression events or all-cause death. Solid line Multivitamin arm, broken line Placebo

Four hundred participants were randomized, 200 onto MV and 200 onto placebo. By month 18, the average change in CD4 cell count in the MV arm was 141 cells/uL compared to 147 cells/uL in the placebo arm, a mean difference of −6 · 17 [95 % CI −29 · 3, 16 · 9]. The average change in weight in the MV arm was 3 · 9 kg compared to 3 · 3 kg in the placebo arm, a mean difference of 0 · 54 [95 % CI −0 · 40, 1 · 48]; whereas average change in QoL scores in the MV arm was 6 · 8 compared to 8 · 8 in the placebo arm, a mean difference of −2.16 [95 % CI −4 · 59,0 · 27]. No significant differences were observed in these primary endpoints, or in occurrence of adverse events between the trial arms.

One RDA of MV supplementation was safe but did not have an effect on indicators of disease progression among HIV infected adults initiating HAART.

Read more at:   http://ht.ly/R5X6p HT @MakerereU